title: Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB/c mice against Leishmania chagasi and Leishmania amazonensis challenge.
abstract: Leishmania chagasi and Leishmania amazonensis are the etiologic agents of different clinical forms of human leishmaniasis in South America. In an attempt to select candidate antigens for a vaccine protecting against different Leishmania species, the efficacy of vaccination using Leishmania ribosomal proteins and saponin as adjuvant was examined in BALB/c mice against challenge infection with both parasite species. Mice vaccinated with parasite ribosomal proteins purified from Leishmania infantum plus saponin showed a specific production of IFN-γ, IL-12 and GM-CSF after in vitro stimulation with L. infantum ribosomal proteins. Vaccinated mice showed a reduction in the liver and spleen parasite burdens after L. chagasi infection. After L. amazonensis challenge, vaccinated mice showed a decrease of the dermal pathology and a reduction in the parasite loads in the footpad and spleen. In both models, protection was correlated to an IL-12-dependent production of IFN-γ by CD4(+) and CD8(+) T cells that activate macrophages for the synthesis of NO. In the protected mice a decrease in the parasite-mediated IL-4 and IL-10 responses was also observed. In mice challenged with L. amazonensis, lower levels of anti-parasite-specific antibodies were detected. Thus, Leishmania ribosomal proteins plus saponin fits the requirements to compose a pan-Leishmania vaccine.
authors.affiliation: Departamento de Farmacologia, Universidade Federal de Minas Gerais, 31.270-901, Belo Horizonte, Minas Gerais, Brazil.
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Chávez-Fumagalli
authors.forename: Mariana A F
authors.initials: MA
authors.lastname: Costa
authors.forename: Dulcilene M
authors.initials: DM
authors.lastname: Oliveira
authors.forename: Laura
authors.initials: L
authors.lastname: Ramírez
authors.forename: Lourena E
authors.initials: LE
authors.lastname: Costa
authors.forename: Mariana C
authors.initials: MC
authors.lastname: Duarte
authors.forename: Vivian T
authors.initials: VT
authors.lastname: Martins
authors.forename: Jamil S
authors.initials: JS
authors.lastname: Oliveira
authors.forename: Carlos C
authors.initials: CC
authors.lastname: Olortegi
authors.forename: Pedro
authors.initials: P
authors.lastname: Bonay
authors.forename: Carlos
authors.initials: C
authors.lastname: Alonso
authors.forename: Carlos A P
authors.initials: CA
authors.lastname: Tavares
authors.forename: Manuel
authors.initials: M
authors.lastname: Soto
authors.forename: Eduardo A F
authors.initials: EA
authors.lastname: Coelho
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002478:Cells, Cultured; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D005528:Foot / Q000469:parasitology / Q000473:pathology; D018314:Leishmania infantum / Q000276:immunology* / Q000472:pathogenicity; D007894:Leishmania mexicana / Q000276:immunology* / Q000472:pathogenicity; D007896:Leishmaniasis / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D054332:Leishmaniasis Vaccines / Q000276:immunology* / Q000302:isolation & purification; D008264:Macrophages / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009569:Nitric Oxide / Q000096:biosynthesis; D015800:Protozoan Proteins / Q000276:immunology / Q000302:isolation & purification; D012269:Ribosomal Proteins / Q000276:immunology* / Q000302:isolation & purification; D012503:Saponins / Q000008:administration & dosage
chemical_list: D000276:Adjuvants, Immunologic; D016207:Cytokines; D054332:Leishmaniasis Vaccines; D015800:Protozoan Proteins; D012269:Ribosomal Proteins; D012503:Saponins; D009569:Nitric Oxide